Asthma
Conditions
Brief summary
The study will assess three different nebulizers for use in methacholine challenge testing in order to determine if the Aeroneb Solo would make a suitable replacement for the long-used and now obsolete Wright and Bennett-Twin nebulizers. Results from each device will be compared to evaluate whether current guidelines for the methacholine challenge should be updated for superior standardization.
Detailed description
Sixty asthmatics (20 at each testing site: University of Saskatchewan, McMaster University, Laval University) will be recruited to undergo this randomized, triple cross-over study. Three nebulizers will be tested, the Wright, the Bennett-Twin and the new Aeroneb Solo. Breakdown of study procedure: Participants will undergo three (potentially four) methacholine challenges, one with each nebulizer in randomized order. An additional methacholine challenge may be performed for screening purposes if the participant has not undergone methacholine challenge testing in one of the participating labs in the previous 6 months. The screening challenge will be performed with the standard nebulizer used at the given testing site (i.e. the Wright or the Bennett-Twin). The methacholine challenges performed with the Wright and Bennett-Twin nebulizers will follow the two-minute tidal breathing protocol as outlined in the 1999 American Thoracic Society Guidelines for Methacholine Challenge Testing. The testing protocol used with the Aeroneb solo will be identical save for a 1 min inhalation period instead of 2 min. Each challenge will be stopped when a participant's forced expiratory volume in 1 second (FEV1) drops at least 20%. This will allow for the determination of the participant's PC20 (provocative concentration of methacholine causing a 20% fall in FEV1), which will subsequently be converted to a PD20 (provocative dose) value. A minimum 24-hour washout period between challenges will be enforced.
Interventions
DEVICEWright nebulizer
Roxon Medi-Tech, Montreal, QC, Canada
DEVICEBennett-Twin nebulizer
Puritan Bennett Corp., Carlsbad, CA, USA
DEVICEAeroneb Solo
Aerogen Ltd., Galway, Ireland
Sponsors
University of Saskatchewan
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women aged 18 or older * Stable asthma * Baseline methacholine PC20 less than or equal to 16mg/mL * Baseline lung function greater than 65% predicted
Exclusion criteria
* Use of long-acting bronchodilators within 30 days of Visit 1 * Pregnant or nursing * Cardiovascular problems * Respiratory illness within 4 weeks of Visit 1 * Allergen-induced asthma exacerbation within 4 weeks of Visit 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| airway responsiveness to methacholine (methacholine pd20) | Two weeks | methacholine pd20 data will be compared between nebulizers (Wright, Bennett and Solo). Methacholine PD20 data generated with the Wright nebulizer will serve as the comparator for the methacholine pd20 generated with the Bennett and the Solo nebulizers. |
Countries
Canada
Outcome results
None listed